BMS withdraws EU application for Ixempra in breast cancer
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb has withdrawn its EU marketing application for its novel chemotherapy agent Ixempra (ixabepilone) to treat locally advanced or metastatic breast cancer after failure of previous chemotherapy drugs.